LFG
RARE icon

Larson Financial Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

Larson Financial Group’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.41K Buy
192
+50
+35% +$1.24K ﹤0.01% 2656
2026
Q1 		$2.98K Buy
142
+2
+1% +$45 ﹤0.01% 2834
2025
Q4 		$3.22K Sell
140
-301
-68% -$9.9K ﹤0.01% 2641
2025
Q3 		$13.3K Buy
441
+203
+85% +$6.09K ﹤0.01% 1873
2025
Q2 		$8.65K Sell
238
-355
-60% -$12.8K ﹤0.01% 1875
2025
Q1 		$21.5K Buy
593
+568
+2,272% +$23.6K ﹤0.01% 1335
2024
Q4 		$1.05K Buy
25
+8
+47% +$397 ﹤0.01% 2038
2024
Q3 		$944 Hold
17
– – ﹤0.01% 2004
2024
Q2 		$699 Buy
+17
New +$726 ﹤0.01% 1774

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Larson Financial Group's RARE Position: Q2 2026 in Review

Larson Financial Group increased its Ultragenyx Pharmaceutical (RARE) stake by 35% in Q2 2026, buying an estimated $1.24K and bringing the position to 192 shares worth $6.41K. The position accounts for ﹤0.01% of the portfolio, ranked #2656.

Larson Financial Group first reported a position in RARE in Q2 2024 and has held it in 9 quarters since. The position peaked at $21.5K in Q1 2025. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Larson Financial Group held 192 shares of Ultragenyx Pharmaceutical worth $6.41K as of Q2 2026.
  • Larson Financial Group bought 50 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $1.24K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #2656 holding.
  • Larson Financial Group first reported a position in Ultragenyx Pharmaceutical in Q2 2024 and has held it in 9 quarters since.
  • Larson Financial Group's Ultragenyx Pharmaceutical position peaked at $21.5K in Q1 2025.
  • 310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.